Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway
Clinical cancer research : an official journal of the American Association for Cancer Research (2011) - Comments
pubmed: 21106726  doi: 10.1158/1078-0432.ccr-10-2572  issn: 1078-0432  issn: 1557-3265 

Giorgio Zauli, Rebecca Voltan, Raffaella Bosco, Elisabetta Melloni, Sandra Marmiroli, Gian Matteo Rigolin, Antonio Cuneo, Paola Secchiero